Recce Pharmaceuticals Ltd. (AU:RCE) has released an update.
Recce Pharmaceuticals Ltd has announced its participation in the 2024 Military Health System Research Symposium, where it will present findings on RECCE 327, a synthetic anti-infective showing promise against drug-resistant pathogens in wound infections. The company will also highlight the recent recommendation by the US Department of Defence for grant funding to accelerate the development of R327G, a gel for treating burn wound infections. This development underlines Recce Pharmaceuticals’ significant strides in advancing military health research and addressing the critical medical needs of soldiers.
For further insights into AU:RCE stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
